Previous close | 147.37 |
Open | 150.11 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 146.93 - 147.40 |
52-week range | 146.93 - 147.40 |
Volume | |
Avg. volume | N/A |
Market cap | 2.191B |
Beta (5Y monthly) | 0.68 |
PE ratio (TTM) | 0.21 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Big pharma executives are worried that one part of the Inflation Reduction Act will reduce their companies' profits.
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
It has been more than nine years since Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV). The move has worked out well for AbbVie, which today has a larger market capitalization than Abbott's. But how has it worked out for Abbott, and would its investors have made the right move if they bought $25,000 worth of shares in the company back then? In 2021, Abbott generated $7.7 billion in revenue from its COVID-19 testing products, which accounted for 18% of its $43.1 billion in total sales.